Physician profile
Haley Holsinger
NPI 1639800204
$1,476.36
in general payments reported to CMS, 2019-2025
16 companies · $52.81 in 2025
The $52.81 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,271 · 2023: $153 · 2025: $52.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $205.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $322.07 | 2022 | |
| Sanofi-Aventis U.S. LLC | $230.70 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $217.26 | 2022-2023 | |
| Lilly USA, LLC | $163.57 | 2022-2023 | Mounjaro, Trulicity |
| Amneal Pharmaceuticals LLC | $155.69 | 2022-2023 | Unithroid |
| Novartis Pharmaceuticals Corporation | $67.61 | 2023-2025 | |
| Mannkind Corporation | $67.05 | 2022-2023 | Afrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.20 | 2022 | |
| Corcept Therapeutics | $46.89 | 2022 | |
| Abbvie INC. | $45.07 | 2022 | |
| Medtronic, INC. | $24.18 | 2022 | |
| Amgen INC. | $21.01 | 2023 | Prolia, Evenity |
| Ultragenyx Pharmaceutical INC. | $19.87 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $18.97 | 2022 | |
| Merck Sharp & Dohme LLC | $18.52 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $7.70 | 2023 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haley Holsinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.